



CERTIFICATION OF ANALYSIS	
Product: Tirzepatide 72mg/4mL 18mg/mL (4mL fill)	NDC: 84139-218-04
Test Date: 17 Nov 2025	Batch No.: ProRx11112025@2
Date of Mfg: 11 Nov 2025	Date of Exp: 11 Nov 2026

Test	Specification	Result
Appearance	Clear solution	Conforms
Tirzepatide content	16.2 to 19.8 mg/mL	17.7 mg/mL
Phenol content	4.5 to 5.5 mg/mL	5.0 mg/mL
Sterility by ScanRDI	Conforms to sterility test as per USP <71>	Pass
Endotoxin	Conforms to specifications as per USP <85>	Pass
Particulate	Conforms to specifications as per USP <788>	Pass

**Results excluding appearance transcribed from third-party testing from Prompt Praxis Laboratories.**

**Conclusion: Test results comply with product specifications**

Approved by: Initials/Date	<i>al fuchs</i>	2025-11-18
Reviewed by: Initials/Date	<i>Jennifer Wagner</i>	2025-11-18

# Audit trail

## Details

FILE NAME COA- Tirzepatide 72mg/4mL ProRx11112025@2 - 18/11/2025, 14:19

STATUS ● Signed

STATUS TIMESTAMP 2025/11/18  
20:37:56 UTC

## Activity



SENT

cynthia@prorxpharma.com **sent** a signature request to:

- Jennifer Wagner (jennifer@prorxpharma.com)
- al fuchs (al@prorxpharma.com)

2025/11/18  
19:19:10 UTC



SIGNED

**Signed** by Jennifer Wagner (jennifer@prorxpharma.com)

2025/11/18  
20:37:56 UTC



SIGNED

**Signed** by al fuchs (al@prorxpharma.com)

2025/11/18  
20:12:59 UTC



COMPLETED

This document has been signed by all signers and is **complete**

2025/11/18  
20:37:56 UTC

The email address indicated above for each signer may be associated with a Google account, and may either be the primary email address or secondary email address associated with that account.